Evidence map›Paper›PMID 42255597›Full record

ArticleACS omega2026

MolFoundry: A Structure-Aware Generative Framework for De Novo Design of PRRSV Nucleocapsid Candidate Binders.

Jindong Hao, Weibo Jin

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jindong HaoCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.ORCID https://orcid.org/0009-0009-0147-8114
Weibo JinCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.ORCID https://orcid.org/0000-0002-7004-0847

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationdespite being one of the most economically devastating swine pathogens, porcine reproductive and respiratory syndrome virus (PRRSV) currently lacks approved antiviral therapeutics. The viral nucleocapsid (N) protein, being structurally conserved and indispensable for genome packaging, presents an attractive yet underexplored target for small-molecule inhibitor design. However, contemporary generative frameworks are predominantly structure-agnostic, frequently failing to reconcile geometric complementarity with drug-likeness and synthetic accessibility.

resultshere, we present MolFoundry, a structure-aware de novo molecular design framework. MolFoundry integrates an SE(3)-equivariant pocket-ligand affinity scorer, a pocket-conditioned cross-attention generator, and a deterministic multiobjective optimization module guided by Pareto ranking and medicinal chemistry constraints. Trained on a comprehensive data set of 18,412 PDBbind complexes and specifically deployed against the PRRSV N-protein pocket, the framework generates highly diverse, synthetically tractable molecules with superior geometric consistency. Crucially, MolFoundry outperforms state-of-the-art diffusion, transformer, and reinforcement learning baselines across key metrics, achieving exceptional validity (0.938), perfect novelty (1.000), robust internal diversity (0.918), and highly favorable predicted binding affinity (-9.201 kcal/mol). Comprehensive ablation studies further substantiate that explicit pocket conditioning and multiobjective optimization are paramount for securing balanced pharmacological and affinity profiles. Data and software availability: MolFoundry is a Python-based molecular generation framework. The project code and documentation are available in the GitHub repository at https://github.com/hjd20030114-blip/MolFoundry.git under the MIT License.

Identifiers

PMID42255597
PMCPMC13234906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.